Targeting cancer and autoimmune diseases

Our goal is to improve the treatment and the quality of life in patients with debilitating diseases.

Machavert’s Science Approach

We are creating novel drug substances that will take advantage of small molecules and phospholipids in the areas indicated in the diagram; the precision medicine, autoimmunity and immuno-oncology, and targeted drug delivery.


Who we are

Our mission and our goals

Machavert is a bio-pharmaceutical company that develops novel, first-in-class therapeutics to treat cancer and autoimmune diseases. Our approach takes advantage of novel substances that inhibit cancer growth, interact with the human immune system or enhance the targeting and efficacy of other therapeutics.

Our primary goal is to improve the quality of life of patients suffering from difficult to treat cancers or autoimmune disorders. Machavert currently focuses on preclinical research and development to build a robust portfolio of drug candidates for clinical trials.

Our drug candidates

Machavert is developing new classes of therapies for precision medicine in cancer and immuno-oncology. Our portfolio includes RAL GTPase inhibitors for targeting KRAS mutant cancers, including non-small cell lung cancer (NSCLC) and colorectal cancer. The RAL GTPase inhibitor technology was exclusively in-licensed from the University of Colorado School of Medicine (CU) and represents a novel way of drugging KRAS mutant cancers that collectively comprise 30% of all cancers. The portfolio also includes novel bioactive phospholipids that activate natural killer (NK) cells that are in development for immuno-oncology. The bioactive lipids are formulated as nanoparticles that preferentially circulate to tumors. These nanoparticles can be formulated with small molecule therapeutics for increased tumor delivery and efficacy. A CHK2 inhibitor therapeutic is being combined with the nanoparticles for the treatment of ovarian cancer.

Creativity, collaboration and innovation.

At Machavert, we believe that the key to our success is a close collaboration in a creative team.

We are a group of passionate innovators with multidisciplinary expertise; focused on the challenge to create new ways to treat cancer and autoimmune diseases with unmet medical needs.

  • Creativity
  • Collaboration
  • Innovation


We have partnered with leading firms to provide us with additional expertise, guidance and resources.

  • Highlighted Partnerships